Eli Lilly launched its oral obesity drug three months ago, but market data shows most patients are choosing Novo Nordisk's pill instead. The shift gives Novo a competitive edge in the billion-dollar weight-loss drug market after losing the lead in injectable GLP-1 treatments to Lilly.
Eli Lilly launched its oral obesity drug three months ago, but market data shows most patients are choosing Novo Nordisk's pill instead. The shift gives Novo a competitive edge in the billion-dollar weight-loss drug market after losing the lead in injectable GLP-1 treatments to Lilly.
Novo Nordisk's oral obesity pill has captured the majority of new patients three months after Eli Lilly launched its competing treatment, market data show.
"Novo's oral GLP-1 has demonstrated superior early adoption, suggesting physicians and patients favor its efficacy profile over Lilly's offering," Sam Goldstein, a healthcare analyst, said.
Novo Nordisk was first to market with an injectable GLP-1 weight-loss drug but lost its lead to Lilly in that fast-growing category. The Danish drugmaker has since pivoted to the oral segment, where its pill now appears to outperform Lilly's in head-to-head comparisons. Novo Nordisk carries a trailing 12-month dividend payout ratio of 40 percent and offers a 3.5 percent yield, providing income cushion as it navigates the competitive landscape.
The outcome reshapes revenue forecasts in the obesity treatment sector, a market projected to exceed $100 billion annually by the end of the decade. Lilly, which dominates the injectable GLP-1 market, now faces the risk that its oral drug fails to gain the same traction. For Novo Nordisk, the early lead in pills offers a chance to reclaim market share in one of the pharmaceutical industry's most closely watched drug categories. Investors will watch upcoming prescription data and any head-to-head clinical readouts for further signals on long-term market share trends.
This article is for informational purposes only and does not constitute investment advice.
